Insider Sell: Enochian Biosciences
7:23AM ET 5/23/2022 MT NewswiresSerhat Gumrukcu, 10% Owner, on May 18, 2022, sold 253,493 shares in Enochian Biosciences (ENOB) for $2,027,944. Following the Form 4 filing with the SEC,...
Quotes Snapshot > ENOB
Enochian Biosciences Inc ENOB:NASDAQ
Last Price$2.77NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
Today's Change+0.10(3.75%)
Bid (Size)$2.77 (2)
Ask (Size)$2.86 (3)
Day Low / High$2.59 - 2.85
Volume63.1 K
Read more news Recent News
Insider Buy: Enochian Biosciences
7:22AM ET 5/23/2022 MT NewswiresRene Sindlev, 10% Owner, Director, on May 18, 2022, executed a purchase for 253,493 shares in Enochian Biosciences (ENOB) for $2,027,944. Following the...
Sector Update: Health Care Stocks Lower In Monday's Premarket Activity
9:15AM ET 2/14/2022 MT NewswiresHealth care stocks were lower premarket Monday. The Health Care SPDR (XLV) was down by 0.03% and the iShares Biotechnology ETF (IBB) was slipping by 0.39%...
Enochian Biosciences Files for Shelf Offering of Up to $100 Million Common Shares
3:11AM ET 2/14/2022 MT NewswiresEnochian Biosciences (ENOB) late Friday registered with the US Securities and Exchange Commission for a shelf offering of up to $100 million of common...
View all Commentary and Analysis
No news stories available at this time.
Company Profile
Business DescriptionEnochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA. View company web site for more details
| Address | 2080 Century Park East Los Angeles, California 90067-2012 |
| Phone | +1.305.918.1980 |
| Number of Employees | 4 |
| Recent SEC Filing | 08/03/2022 4 |
| Executive Vice Chairman & Chief Executive Officer | Mark Richard Dybul |
| Chief Financial Officer | Luisa Puche |
| Senior Vice President-Clinical Operations | Greg Duczynski |
| Executive Vice President-Research & Development | François Binette |
Company Highlights
| Price Open | $2.65 |
| Previous Close | $2.67 |
| 52 Week Range | $1.42 - 13.78 |
| Market Capitalization | $146.7 M |
| Shares Outstanding | 52.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 09/23/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.67 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -24.27% |